Liraglutide
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
Novo Nordisk · Phase 2 · Completed · Enrollment 957
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Sema 0.05 mg | n/r | n/r | n/r | n/r | n/r |
| Sema 0.1 mg | n/r | n/r | n/r | n/r | n/r |
| Sema 0.2 mg | n/r | n/r | n/r | n/r | n/r |
| Sema 0.3 mg | n/r | n/r | n/r | n/r | n/r |
| Sema 0.4 mg | n/r | n/r | n/r | n/r | n/r |
| Sema 0.3 mg (fast dose escalation) | n/r | n/r | n/r | n/r | n/r |
| Sema 0.4 mg (fast dose escalation) | n/r | n/r | n/r | n/r | n/r |
| Lira 3.0 mg | n/r | n/r | n/r | n/r | n/r |
| Placebo Sema 0.05 mg | 32 participants | 8 participants | 20 participants | n/r | 0 |
| Placebo Sema 0.1 mg | 42 participants | 18 participants | 25 participants | n/r | 0 |
| Placebo Sema 0.2 mg | 45 participants | 24 participants | 35 participants | n/r | 0 |
| Placebo Sema 0.3 mg | n/r | n/r | n/r | n/r | n/r |
| Placebo Sema 0.4 mg | n/r | n/r | n/r | n/r | n/r |
| Placebo Sema 0.3 mg (fast dose escalation) | 43 participants | 11 participants | 27 participants | n/r | 0 |
| Placebo Sema 0.4 mg (fast dose escalation) | 49 participants | 17 participants | 38 participants | n/r | 0 |
| Placebo Lira 3.0 mg | 46 participants | 11 participants | 29 participants | n/r | 0 |
A count stays a count. This page does not turn a count into a percent.